REFILE-Merck aborts development of osteoporosis drug due to stroke risk

Sept 2 (Reuters) - Merck & Co Inc said it would

cease the development of its experimental osteoporosis drug

after an independent analysis confirmed that the therapy was

associated with an increased risk of stroke.

Read more